

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. - 10. (Canceled)

11. (Currently Amended): An isolated protein comprising the polypeptide of SEQ ID NO: [[NOS:]] 7,11,15,19 or 23.

12. - 46. (Canceled)

47. (Currently Amended): The protein of claim 11, wherein the protein is O-linked [[with]] to β -(1-3)-Gal-GalNac.

48. (Previously Presented): A composition comprising a therapeutically effective amount of a protein of claim 47 in a pharmaceutically acceptable carrier.

49. (Previously Presented): The composition of claim 48, additionally comprising hyaluronan or hylan.

50. (Previously Presented): The composition of claim 48, wherein the composition is formulated for injection.

51. (Previously Presented): The composition of claim 48, wherein the composition is encapsulated.

52. (Currently Amended): The composition of claim [[48]] 51, wherein the composition further comprises a matrix is encapsulated in an implantable drug delivery matrix.

53. (Previously Presented): The composition of claim 48, wherein the composition further comprises a local anesthetic.

54. (Previously Presented): The composition of claim 48, wherein the composition further comprises a cytokine.

55. (Previously Presented): The composition of claim 48, wherein the composition further comprises a lymphokine.

56. (Currently Amended): The composition of claim 48, wherein the composition further comprises a thromolytic thrombolytic factor.

57. (Previously Presented): The composition of claim 48, wherein the composition further comprises an antithrombolytic factor.

58. (Previously Presented): The composition of claim 48, wherein the composition further comprises an anti-inflammatory agent.

59. (New): The composition of claim 48, wherein the composition further comprises an antibiotic.

60. (New): The composition of claim 48, wherein the composition further comprises a growth factor.